Retatrutide 20mg

Retatrutide 20mg – GLP-1/GIP/Glucagon Triple Agonist

Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly that simultaneously acts on GLP-1, GIP, and glucagon receptors. In the Phase 3 TRIUMPH-1 clinical trial (May 2026), Retatrutide delivered the strongest published weight-reduction data for any medication to date.

This 20mg vial provides sufficient substance for medium-length studies and dosage comparisons.

Mechanism of action

By simultaneously activating three metabolic pathways, Retatrutide exerts a synergistic effect on energy balance, insulin sensitivity, and fat breakdown. In TRIUMPH-1, participants on the 12 mg dose lost on average 28.3 % of their body weight after 80 weeks — in participants with a BMI ≥35 even up to 30.3 % after 104 weeks. Even lower doses showed strong effects: 9 mg → 25.9 %, 4 mg → 19.0 %.

Technical specifications

Storage: Store at −20 °C (long-term); after reconstitution at 4 °C, use within 2–4 weeks. Protect from light and moisture.

Source: Eli Lilly TRIUMPH-1 Phase 3 study, May 2026

Disclaimer: Not intended for human or veterinary use. For laboratory research purposes only. Not for diagnostic or therapeutic purposes.

Reconstitution note 20 mg: This vial size offers a higher yield per reconstitution and is suitable for medium-term experimental series with multiple measurement points, without the need to restart in between.

Reconstitution: Example calculation

To achieve a working concentration of 10 mg/ml, reconstitute the 20 mg vial with 2 ml of sterile bacteriostatic water (BAC water). Slowly inject the water along the inside of the vial and gently swirl it instead of shaking it to avoid damaging the peptide structure. Detailed step-by-step instructions can be found in our user manual.

Frequently Asked Questions

Why choose 20 mg instead of 10 mg?
In trials with multiple repetitions or longer observation periods, the larger quantity of vials reduces the number of necessary reorders.

Does the reconstitution solution change with the quantity?
No — the principle remains the same, only the amount of sterile solvent is adjusted proportionally to the vial size (see example calculation).

Quality assurance

Each production batch undergoes independent dual testing: HPLC analysis (High Performance Liquid Chromatography) to determine purity and LC-MS analysis (Liquid Chromatography Mass Spectrometry) to definitively verify molecular mass and correct peptide sequence. Only after passing these tests is a batch released.